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Sarcopenia is associated with poor 
prognosis after chemoradiotherapy 
in patients with stage III 
non‑small‑cell lung cancer: 
a retrospective analysis
Kuniaki Katsui1*, Takeshi Ogata2, Soichi Sugiyama3, Kotaro Yoshio3, Masahiro Kuroda4, 
Takao Hiraki5, Katsuyuki Kiura6, Yoshinobu Maeda7, Shinichi Toyooka8 & Susumu Kanazawa5
We intended to investigate whether muscle and adipose masses were associated with prognosis 
among patients with stage III non‑small‑cell lung cancer (NSCLC) who were undergoing 
chemoradiotherapy (CCRT). We retrospectively explored data of patients with stage III NSCLC who 
underwent definitive CCRT (≥ 60 Gy) between January 2004 and March 2018 at our hospital. We 
examined the relationship of overall survival (OS) with body mass index (BMI), skeletal muscle index 
(SMI), psoas muscle index (PMI), visceral adipose tissue index (VAI), subcutaneous adipose tissue 
index (SAI), and visceral‑to‑subcutaneous adipose tissue area ratio (VSR) using log‑rank tests for 
the univariate analysis and Cox proportional hazard models for the multivariate analysis. Overall, 
16, 32, and 12 patients had stage IIIA, IIIB, and IIIC NSCLC, respectively. The total radiotherapy dose 
ranged from 60 Gy/30 fractions to 66 Gy/33 fractions. In the univariate analysis, the performance 
status (PS), BMI, and SMI were associated with OS, whereas the PMI, VAI, SAI, and VSR were not. 
In the multivariate analysis, the PS and SMI were associated with OS. The hazard ratios and 95% 
confidence intervals were 2.91 and 1.28–6.64 for PS, and 2.36 and 1.15–4.85 for SMI, respectively. 
The 1, 3, and 5‑year OS rates were 92.1%, 59.6%, and 51.0% in patients with high SMI, and 63.6%, 
53.8%, and 17.9% in patients with low SMI, respectively. The SMI correlated with prognosis in our 
study population, whereas adipose mass did not. Therefore, sarcopenia should be considered while 
predicting the OS in such patients.
The incidence of lung cancer is increasing worldwide, with 1.6 million cases reported in 2008 and 2.1 million in 
 20181,2. The age-standardized 5-year overall survival (OS) rate associated with lung cancer is as low as 10–20%, 
and the disease remains associated with poor  prognosis3; therefore, there is an urgent need to develop effective 
prognostic and management strategies.
Sarcopenia, first defined by  Rosenberg4, is the loss of muscle mass in association with aging, decreased activity 
levels, malnutrition, organ failure, and diseases such as  malignancies5,6. An association between sarcopenia and 
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adverse health effects, including falls, disability, hospitalization, long-term care placement, poor quality of life, 
and mortality has been  confirmed6. Sarcopenia is also associated with poor prognosis after treatment for malig-
nancies, including lung  cancer7–13. Further, an association between sarcopenia and poor prognosis in surgical 
cases, especially those involving early-stage lung cancer, has been demonstrated in many  studies12,13. In a study 
by Baracos et al., 46.8% of the patients with stage III–IV non-small-cell lung cancer (NSCLC) were diagnosed 
with  sarcopenia14. Concurrent chemoradiotherapy (CCRT) is among the standard treatments for stage III lung 
 cancer15,16. Few studies have focused on the association between prognosis and sarcopenia in patients with 
NSCLC who were treated with chemoradiotherapy. Bowden et al. demonstrated that muscle attenuation, and not 
muscle mass, was associated with long-term survival in patients with lung cancer, including those with small-cell 
lung cancer and NSCLC, who underwent  chemoradiotherapy17. Kiss et al. did not identify an association between 
muscle mass or muscle attenuation and OS in patients with NSCLC who underwent CCRT 18. Existing evidence 
on the association between sarcopenia and OS in patients treated with CCRT for stage III NSCLC is insufficient.
Body mass index (BMI)-determined obesity is a poor prognostic factor after treatment in most cancer 
 types19,20. However, the relationship between obesity and OS after treatment in patients with lung cancer is 
 controversial19,20. In a meta-analysis, Gupta et al. showed that patients with obesity and overweight had lower 
lung cancer mortality rates than those with normal  BMI21. Dahlberg et al. showed that patients with advanced 
NSCLC and obesity who received chemotherapy had better OS than those without obesity in the early stages of 
their  study22. In locally advanced NSCLC settings, Lam et al. showed that the OS of patients who were obese was 
better than that of those who were normal-weight23. In the aforementioned studies, obesity was assessed based on 
BMI alone without using computed tomography (CT). In recent years, sarcopenia and adiposity have been meas-
ured based on muscle and fat masses using CT, which is necessary for diagnosing and staging  cancer7,11,17,18,24–26. 
Although BMI is not a poor prognostic factor, the visceral-to-subcutaneous adipose tissue mass, in addition to 
muscle mass, is an independent poor prognostic factor in patients with hepatocellular carcinoma and intrahepatic 
 cholangiocarcinoma25,26. Because weight includes components besides muscles, the measurement of fat mass 
in addition to muscle mass using CT is desirable. However, no studies to date have examined the association 
between fat mass and OS in patients with NSCLC who were treated with CCRT.
The identification of the level of risk before treatment and provision of appropriate interventions for sarcope-
nia and obesity may improve patient prognosis. Therefore, we intended to investigate whether CT-determined 
muscle and fat masses were prognostic factors in patients with stage III NSCLC who have undergone CCRT.
Patients and methods
Patients and treatment. We retrospectively explored data of patients with stage III NSCLC who under-
went definitive CCRT (≥ 60 Gy) between January 2004 and March 2018 at our hospital. This study included 
patients for whom pre-CCRT digital plain CT of the third lumbar vertebra (L3) was available in the picture 
archiving and communication systems. Patients who underwent treatment for NSCLC before CCRT and those 
who received preoperative CCRT with chest surgery before recurrence were excluded. Staging was determined 
using the tumor-node-metastasis classification, 8th edition. We examined the patients’ histology, smoking his-
tory, performance status (PS), location, laterality, and forced expiratory volume in 1 s. The indication of CCRT 
was determined by consensus of board-certified respiratory physicians and radiation oncologists. The chemo-
therapy regimen was determined by board-certified respiratory physicians, and details regarding radiotherapy 
were finally determined by board-certified radiation oncologists. Chemotherapy mainly involved the adminis-
tration of cisplatin plus docetaxel; tegafur/gimeracil/oteracil was used for vulnerable patients. All patients were 
treated with three-dimensional conformal radiotherapy. Details regarding the three-dimensional radiotherapy 
which was employed have been described  elsewhere27. The gross tumor included the primary tumor and the 
clinically diagnosed metastatic lymph node. The margin for the clinical target volume was 5–10 mm, and sub-
carinal and ipsilateral hilar nodal stations were included in cases of elective nodal irradiation. The internal mar-
gin was determined using fluoroscopic images, and the planning target volume margin was 5–10 mm. We used 
a 10 MV photon beam generated from a linear accelerator (Primus or ONCOR, or Mevatron, Canon Medical 
Systems, Tochigi, Japan).
All procedures were performed according to the ethical standards set out in the 1964 Declaration of Helsinki 
and subsequent amendments. This study was approved by our institutional review board of Okayama Univer-
sity Graduate School of Medicine, Dentistry and Pharmaceutical Sciences and Okayama University Hospital 
(approval number 1809-018). Written informed consent for CCRT was obtained from all patients before treat-
ment. The choice to opt out was provided through notifications displayed on the hospital’s website and in the 
outpatient ward before starting the study.
Image analysis. Abdominal CT data, which were obtained from the institution’s picture archiving and com-
munication systems, were transferred to a workstation computer (SYNAPSE VINCENT version 5.5, FUJIFILM 
Medical Co., Ltd., Tokyo, Japan). Plain CT was used to examine the vertebra at the L3 level, and contours were 
extracted automatically by setting the Hounsfield unit (HU) thresholds within a certain range. According to 
previous studies, the HU thresholds were set from − 29 to + 150 for the skeletal and psoas muscles, − 150 to − 50 
for visceral adipose tissues, and − 190 to − 30 for subcutaneous adipose  tissues7,24. Skeletal muscles included all 
muscles at the L3 level. Areas that were not obviously targeted muscle or adipose tissues were deleted by manual 
manipulation. Figure 1A–D illustrate an example for each of the muscle and adipose tissues. These four areas 
 (cm2) were divided by the square of height (m) to obtain the skeletal muscle index (SMI), psoas muscle index 
(PMI), visceral adipose index (VAI), and subcutaneous adipose index (SAI)25,28. Muscle attenuation (MA), as a 
measure of muscle quality, was defined as the mean of the HU value of the SMI; furthermore, the visceral-to-
subcutaneous adipose ratio (VSR) was  calculated7,25.
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Evaluation and statistical analyses. Cutoff values for continuous variables were calculated based on 
individual time-dependent receiver operating  characteristics29. According to previous  reports26, we calculated 
the cutoff values for men and women and divided them into two groups. The survival curves were obtained 
using the Kaplan–Meier method. We examined the relationship between the aforementioned parameters and OS 
using log-rank tests for the univariate analysis and Cox proportional hazard models for the multivariate analysis. 
Statistical significance was determined at p-values < 0.05 (two-sided). R software version 3.5.1 and additional 
package of survival ROC version 1.0.3 (R Foundation for Statistical Computing, Vienna, Austria) were used for 
all statistical analyses.
Results
This study included 60 eligible patients. Table 1 shows the patients’ characteristics. Overall, 16 patients had stage 
IIIA NSCLC, 32 had stage IIIB, and 12 had stage IIIC. The follow-up period was 29.1 months (2.4–121.4 months) 
from the initiation of CCRT. The total radiotherapy doses were 60 Gy/30 fractions in 59 patients and 66 Gy/33 
fractions in one patient. Details regarding the chemotherapy regimen are shown in Table 1. The median BMI, 
SMI, PMI, MA, VAI, SAI, and VSR were 21.7 kg/m2 (range: 14.2–34.1 kg/m2), 43.1  cm2/m2 (range: 23.5–64.8 
 cm2/m2), 5.1  cm2/m2 (range: 2.7–8.6  cm2/m2), 35.9 HU (range: 8.6–49.0 HU), 27.0  cm2/m2 (0.7–134.4  cm2/m2), 
28.7  cm2/m2 (0.0–127.1  cm2/m2), and 1.0 (range: 0.1–25.8), respectively.
Table 2 shows the relationship between clinicopathologic factors and sarcopenia (low SMI). Sarcopenia was 
significantly associated with lower BMI (p = 0.017). Table 3 shows the cutoff values and the results of the univari-
ate and multivariate analyses of factors associated with OS. The female/male cutoff BMI, SMI, PMI, MA, VAI, 
SAI, and VSR values determined from the time-dependent receiver operating characteristic curve were 17/25 kg/
m2, 24/43  cm2/m2, 4.7/7.3  cm2/m2, 9/36 HU, 97/40  cm2/m2, 127/28  cm2/m2, and 0.8/0.6, respectively. The PS, 
SMI, and BMI were significant prognostic factors associated with OS in the univariate analysis (p = 0.004, 0.01, 
and 0.03), whereas the PMI, MA, VAI, SAI, and VSR were not (p = 0.4, > 0.99, 0.1, 0.09, and 0.1, respectively). In 
the multivariate analysis, the PS and SMI were significant prognostic factors associated with OS (p = 0.011 and 
0.020, respectively). The hazard ratios and 95% confidence intervals (CIs) were 2.91 and 1.28–6.64 for the PS, 
2.36 and 1.15–4.85 for the SMI, respectively. Since BMI and SMI are significantly correlated, we excluded BMI 
from the multivariate analysis according to previous  reports30,31.
Figure 1.  Computed tomography images of the third lumbar vertebra for each area. (a) Green highlights 
indicate the skeletal muscle area for the skeletal muscle index. (b) Green highlights indicate the psoas muscle 
area for the psoas muscle index. (c) Green highlights indicate the visceral adipose tissue area for the visceral 
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Figure 2 shows OS curve for all patients. The 1, 3, and 5-year OS rates were 81.7%, 57.9%, and 37.8%, respec-
tively, for all patients. Further, the 1, 3, and 5-year OS rates were 92.1%, 59.6%, and 51.0% in patients with high 
SMI, and 63.6%, 53.8%, and 17.9% in patients with low SMI, respectively (Fig. 3). Details of the OS rates for 
Table 1.  Patient characteristics. ECOG-PS Eastern Cooperative Oncology Group performance status, FEV1 
forced expiratory volume in 1 s, BMI body mass index, MA mean muscle attenuation, SMI skeletal mass 
muscle index, PMI psoas muscle index, VAI visceral adiposity index, SAI subcutaneous adiposity index, VSR 























Squamous cell carcinoma 28 47















FEV1 (l)a Median (range) 2.15 (0.86–4.11) –
Chemotherapy
Standard 49 82
Cisplatin + Docetaxel 40 67
Cisplatin + Vinorelbine + Nimotuzumab 1 2
Cisplatin + Etoposide 1 2
Cisplatin + Tegafur/Gimeracil/Oteracil 5 8




Radiation dose (Gy) Median (range) 60 (60–66) –
BMIa (kg/m2) Median (range) 21.7 (14.2–34.1) –
SMI  (cm2/m2) Median (range) 43.1 (23.5–64.8)
PMI  (cm2/m2) Median (range) 5.1 (2.7–8.6) –
MA (HU) Median (range) 35.9 (8.6–49.0) –
VAI  (cm2/m2) Median (range) 27.0 (0.7–134.4) –
SAI  (cm2/m2) Median (range) 28.7 (0.0–127.1) –
VSR Median (range) 1.0 (0.1–25.8) –
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sarcopenia are shown in Table 4. The 1, 3, and 5-year survival rates were 90.5%, 85.4%, and 64.3% for the groups 
with a PS of 0, and 75.0%, 44.7%, and 25.6% for the groups with a PS of 1, respectively (p = 0.004).
Discussion
This was the first study to demonstrate that the SMI was associated with OS in patients with stage III NSCLC 
who underwent definitive CCRT. Studies focusing on the relationship between the SMI and OS in patients 
with cancer have predominantly been conducted in gastrointestinal cancer settings. Fujiwara et al. reported 
a significant association of the SMI and MA with mortality in patients with hepatocellular carcinoma, and 
Okumura et al. showed a relationship of the SMI and MA with OS in patients who underwent surgery for 
 cholangiocarcinoma25,26. In terms of lung cancer, several systematic reviews and meta-analyses have focused on 
the association between sarcopenia and OS after treatment for lung cancer. Buentzel et al. conducted an analysis 
of 15 studies on patients with lung cancer (including all stages of NSCLC and small-cell lung cancer), and based 
on the findings of multivariate analysis, reported that patients with lung cancer and sarcopenia had a three-fold 
greater risk of death than those without  sarcopenia8. Yang et al. who conducted an analysis of thirteen studies 
showed that sarcopenia was an independent prognostic factor for poor OS in patients with stage III–IV  NSCLC9. 
Table 2.  Relationship between clinicopathologic factors and sarcopenia. ECOG-PS Eastern Cooperative 
Oncology Group performance status, FEV1 forced expiratory volume in 1 s, BMI body mass index, MA mean 
muscle attenuation, SMI skeletal mass muscle index, PMI psoas muscle index, VAI visceral adiposity index, SAI 
subcutaneous adiposity index, VSR visceral-to-subcutaneous fat ratio, CI confidence interval. a These variables 
have missing values.
Factor With sarcopenia (low SMI) % Without sarcopenia (high SMI) % p value
Sex
Female 1 5 8 21
0.14
Male 21 95 30 79
Age (years)
 < 66 8 36 20 53
0.29
 ≥ 66 14 64 18 47
T stage
X, 1–2 5 23 17 45
0.1
3–4 17 77 21 55
N stage
0–1 6 27 2 5
0.042
2–3 16 73 36 95
Clinical stage
IIIA 6 27 10 26
0.52IIIB 10 45 22 58
IIIC 6 27 6 16
Histology
Adenocarcinoma 8 36 18 47
0.43
Others 14 64 20 53
Smoking  historya
Never/former 15 68 21 53
0.58
Current 7 32 15 47
ECOG-PSa
0 7 32 14 40
0.58
1 15 68 21 60
Laterality
Right 6 73 25 29
0.002
Left 16 27 10 71
Lobe
Upper/middle 18 82 31 82
 > 0.99
Lower 4 18 7 18
FEV1 (l)a
 < 2.2 8 42 21 66
0.15
 ≥ 2.2 11 58 11 34
Chemotherapy
Standard 17 77 32 84
0.51
Reduced 5 23 6 16
BMIa
F: < 17, M: < 25 19 90 22 58
0.017
F: ≥ 17, M: ≥ 25 2 10 16 42
PMI
F: < 4.7, M: < 7.3 21 95 31 82
0.24
F: ≥ 4.7, M: ≥ 7.3 1 5 7 18
MA
F: < 9, M: < 36 11 50 13 34
0.28
F: ≥ 9, M: ≥ 36 11 50 25 66
VAI
F: < 97, M: < 40 18 82 24 63
0.15
F: ≥ 97, M: ≥ 40 4 18 14 37
SAI
F: < 127, M: < 28 15 68 19 50
0.19
F: ≥ 127, M: ≥ 28 7 32 19 50
VSR
F: < 0.8, M: < 0.6 8 36 11 29
0.58
F: ≥ 0.8, M: ≥ 0.6 14 64 27 71
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Those reviews included several treatment modalities, including surgery, stereotactic  radiotherapy10, chemora-
diotherapy, and chemotherapy. Only two studies have considered SMI as an assessment tool for sarcopenia and 
examined its relationship with OS in patients who were treated with chemoradiotherapy. Kiss et al. reported 
that 41 patients with stage I–III NSCLC who received CCRT showed a significant decrease in the SMI and MA 
at 4 weeks after starting treatment and that low MA tended to be associated with poor OS (p = 0.13)18. However, 
the presence of sarcopenia before treatment is not associated with poor OS. Bowden et al. demonstrated that low 
MA was associated with significantly lower OS rates in patients with lung cancer, including those with NSCLC 
and small-cell lung cancer, who were treated with  chemoradiotherapy17. The SMI was not associated with OS 
in Bowden et al.’s17 study as well. In our study, the SMI was a prognostic factor for OS, whereas MA was not. 
The study by Kiss et al. differs from our study with respect to the following aspects: the HU thresholds for SMI 
measurements ranged from − 19 to 150, and they included stage I–III cases. The study by Bowden et al. differs 
Table 3.  Univariate and multivariate analyses of factors associated with overall survival. NE not entered, 
ECOG-PS Eastern Cooperative Oncology Group performance status, FEV1 forced expiratory volume in 1 s, 
BMI body mass index, MA mean muscle attenuation, SMI skeletal mass muscle index, PMI psoas muscle 
index, VAI visceral adiposity index, SAI subcutaneous adiposity index, VSR visceral-to-subcutaneous fat ratio, 
CI confidence interval. a These variables have missing values.
Factor Number of deaths
Univariate analysis Multivariate analysis Hazard ratio






 < 66 16/28
0.6 NE –



































 < 2.2 17/29
0.2 NE –






F: < 17, M: < 25 28/41
0.03 NE –
F: ≥ 17, M: ≥ 25 7/18
SMI
F: < 24, M: < 43 17/22
0.01 0.02
2.36
F: ≥ 24, M: ≥ 43 19/38 (1.15–4.85)
PMI
F: < 4.7, M: < 7.3 31/52
0.4 NE –
F: ≥ 4.7, M: ≥ 7.3 5/8
MA
F: < 9, M: < 36 15/24
 > 0.99 NE –
F: ≥ 9, M: ≥ 36 21/36
VAI
F: < 97, M: < 40 28/42
0.1 NE –
F: ≥ 97, M: ≥ 40 8/18
SAI
F: < 127, M: < 28 23/34
0.09 NE –
F: ≥ 127, M: ≥ 28 13/26
VSR
F: < 0.8, M: < 0.6 8/19
0.1 NE –
F: ≥ 0.8, M: ≥ 0.6 28/41
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from our study with respect to the following aspects: it included sequential chemotherapy cases and CCRT cases, 
patients with small-cell lung cancer, and patients with all disease stages. In addition, the treatment strategies 
for stage III disease vary across institutions, with our institution prioritizing preoperative CCRT plus surgery. 
Therefore, we cannot rule out the possibility that the extent of progression and general condition in our patients 
may have significantly differed from those in patients in the aforementioned reports.
In our study, we included patients with stage III NSCLC who had CT data pertaining to the L3 level, with no 
restrictions on the chemotherapy regimen. Thus, our results may have differed from those of previous studies. 
In our study, the PMI was also not a prognostic factor. Hamaguchi et al. reported that in 541 adult liver donors 
(living donor liver transplantation), the PMI was positively correlated with the  SMI28. Theoretically, if the SMI 
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Figure 2.  Overall survival curve. Proportion of surviving patients shown according to the number of months 
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Figure 3.  Subgroup analysis of overall survival stratified according to SMI. Proportion of surviving patients 
shown according to the number of months after radiotherapy, where the filled line represents a low SMI and the 
dotted line indicates a high SMI. SMI skeletal muscle index, CCRT concurrent chemoradiotherapy.
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why this was not the case. Mitsuyoshi et al. reported that a high PMI was not correlated with high OS (p = 0.873) 
in 89 patients with stage III NSCLC with sex-specific  cutoffs32; therefore, the PMI may not be an important 
parameter in lung cancer. Data on the association of the SMI and PMI with OS in patients with NSCLC are scarce 
in the setting of CCRT compared with surgery, and thus, further studies are warranted.
Muscle loss is a major symptom of cancer cachexia, along with anorexia, weight loss, anemia, and altered car-
bohydrate, lipid, and protein metabolism. Cancer cachexia is recognized as a paraneoplastic syndrome in 60–80% 
of the patients with advanced-stage disease. More than 30% of the patients with cancer die due to cachexia, and 
more than 50% of them die in the presence of cachexia, which is associated with adverse prognosis and shorter 
survival  times33,34. Sarcopenia may be a marker to preemptively predict the development of cancer cachexia. 
Recently, skeletal muscle has been identified as a secretory organ, which secretes myokines that may affect the 
growth of cancer  cells35. Hojman et al. reported that myokines, which are released from muscles during exercise 
inhibit the growth of breast cancer cells and induce apoptosis of these  cells36. Therefore, as muscle mass decreases, 
myokine levels and responses may decrease, making it easier for cancer to progress.
In our study, a higher BMI was correlated with a higher OS rate in the univariate analysis. A high BMI is cor-
related to poor OS after cancer  treatment19; however, there is some controversy regarding the same in patients 
with lung cancer. In their meta-analysis, Gupta et al. showed that patients who were obese in the pre-treatment 
stage had lower lung cancer mortality rates than those with normal weight; our results showed the same trend. 
In gastrointestinal cancers, high VAI, SAI, and VSR have been shown to be associated with poor OS  rates25,26; 
however, no correlation was found in our study that examined data of patients with lung cancer following CCRT. 
The reason for this is that despite difficulties in the performance of simple comparisons, the median VAI and 
SAI values were 31.8  cm2/m2 and 41.4  cm2/m2, respectively, in the study by Fujiwara et al., which are higher than 
the values of 27.0  cm2/m2 and 28.7  cm2/m2, respectively, observed in our study. This may be largely attributed to 
differences in patients’ backgrounds. Regarding OS, the result observed in patients with lung cancer may differ 
from that in those with other carcinomas with respect to adipose mass, as with BMI. In patients undergoing 
CCRT for stage III NSCLC, adipose mass reductions are not given high priority, with efforts primarily driven 
toward increasing or maintaining patients’ muscle mass. To the best of our knowledge, our study was the first 
to examine the association between post-treatment OS rates for lung cancer and the VAI, SAI, and VSR, as 
assessed using CT. In our study, the BMI scores (median 21.7) of all patients were normal, unlike that in the 
study by Martin et al., in which the average BMI scores were 26.0 for men and 25.1 for  women7. Among patients 
with lung cancer and normal BMI, adipose mass may not be related to prognosis; although, further studies on 
adipose mass are warranted.
In the study of Bowden et al., a PS ≥ 2 was associated with poor  OS17. Similarly, in our study, the PS was a 
predictor of prognosis, which is a reasonable result.
Exercise is effective in counteracting the catabolic effects of muscle by increasing the protein synthesis rate 
and decreasing the proteolysis rate owing to its anti-inflammatory  effects37,38. Exercise training can attenuate or 
reverse the process of muscle wasting through anti-inflammatory and antioxidant effects that can attenuate the 
signaling pathways of proteolysis and activate protein synthesis  molecules38. Gould et al. stated in their review 
that exercise successfully improved muscle strength and physical function in patients with cachexia in non-
cancer-related diseases and that exercise interventions provided at various stages of treatment may improve the 
protein synthesis rate and help patients recover from low body weight and reverse  proteolysis37. Delrieu et al. 
reported that participation in a 6-month personalized walking program resulted in significant improvements in 
the 6-min walking distance test (+ 7%) and isometric quadriceps strength (+ 22%) among patients with metastatic 
breast  cancer39. Exercise interventions may aid in increasing or maintaining the muscle strength in patients with 
lung cancer. Future clinical trials are warranted to determine whether improvements in muscle strength can lead 
to OS enhancements.
Our study has some limitations. Since this study was conducted at a single center with a short follow-up 
period, and CCRT is not the only treatment option for stage III NSCLC, the presence of an unmeasured bias 
cannot be ruled out. According to the European Working Group on Sarcopenia in Older People guidelines, the 
diagnosis of sarcopenia requires low muscle strength or low physical performance in addition to low muscle mass; 
however, because of the retrospective nature of the study, muscle strength measurements could not be performed.
In conclusion, we demonstrated that the SMI is correlated with prognosis in patients with stage III lung 
cancer undergoing CCRT, whereas adipose mass is not. The additional consideration of sarcopenia improved 
the predictability degree for OS in our settings, and therefore, could aid in early intervention to maintain muscle 
mass and improve prognosis.
Table 4.  Overall survival rates for sarcopenia. CI confidence interval, OS overall survival, SMI skeletal mass 
muscle index.
year OS (95% CI) for all patients OS with sarcopenia (low SMI) (95% CI) OS without sarcopenia (high SMI) (95% CI)
1 81.7% (72.4–92.1%) 63.6% (46.4–87.3%) 92.1% (83.9–100%)
2 64.1% (52.8–77.7%) 53.8% (36.4–79.7%) 69.7% (56.1–86.6%)
3 57.9% (46.3–72.5%) 53.8% (36.4–79.7%) 59.6% (45.0–78.9%)
4 37.8% (25.9–55.0%) 17.9% (6.6–49.0%) 51.0% (35.7–72.7%)
5 37.8% (25.9–55.0%) 17.9% (6.6–49.0%) 51.0% (35.7–72.7%)
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